ClicBio

About

ClicBio is revolutionizing the treatment of metabolic diseases by targeting the hunger pathway with a groundbreaking mechanism that acts as a pivotal molecular switch, regulating appetite through the modulation of hypothalamic neurons. In preclinical obesity models, inhibiting CLIC1 has been shown to induce weight loss comparable to GLP-1 agonists, while operating through an independent and additive pathway. Research further highlights the additional benefits of CLIC1 inhibition beyond appetite regulation, including increased energy expenditure, a potential reduction in gastrointestinal side effects commonly associated with GLP-1 therapy, and broad anti-inflammatory action. This innovative approach leverages a single small molecule to target multiple aspects of metabolic disease. ClicBio is advancing a portfolio of oral, small-molecule CLIC1 inhibitors toward human clinical testing, paving the way for a new era of hunger-modulating therapeutics that can work alongside or beyond GLP-1 treatments to more effectively combat obesity and metabolic disease.